



# INTERIM REPORT 2024

2024-07-01 until 2024-09-30

Scandinavian Real Heart AB  
556729-5588

# Q3

REALHEART

# Content

3	Significant Events During the Third Quarter of the Year
3	Significant Events After the End of the Period
4	Summary of Interim Report
4	Revenue and Result
4	Financial Position
5	CEO Ina Laura Perkins
6	Scandinavian Real Heart AB
7	Giovanni Lauricella: "One of my Missions is to Help Realheart Attract the Investment Needed to Bring Life-Saving Technology to Market!"
10	Income Statement in Summary - GROUP
11	Balance Sheet in Summary - GROUP
12	Cash Flow Statement in Summary - GROUP
13	Income Statement in Summary - PARENT COMPANY
14	Balance Sheet in Summary - PARENT COMPANY
15	Cash Flow Statement in Summary - PARENT COMPANY
16	Change in Equity - GROUP & PARENT COMPANY

*The 'Company' or 'Realheart' refers to Scandinavian Real Heart AB with organisation number 556729-5588.*

# Significant Events During the Third Quarter of the Year

**At the beginning** of the period, the outcome of the Company's rights issue is published. The outcome shows that 38,083,456 units were subscribed for with unit rights, corresponding to approximately 39.3 percent of the Rights Issue. In addition, the Company has received subscription applications for 5,527,237 units, corresponding to approximately 5.7 percent of the Rights Issue, for subscription without unit rights. Through the Rights Issue, the Company will initially receive approximately SEK 24.3 million before issue costs.

**Halfway into July**, Realheat carries out a directed issue of units to guarantors in connection with the completed rights issue. The Company's Board of Directors, based on the authorization from the Annual General Meeting on June 7, 2024, has decided to issue 6,300,000 units as guarantee compensation directed to a number of the guarantors who provided guarantee commitments in the rights issue of units carried out by the Company during the period June 12 through July 5, 2024, in accordance with the guarantee agreements entered into. Through the directed issue to the underwriters, 6,300,000 warrants of series TO3 are also issued, which entitle to subscribe for a maximum of 3,150,000 shares in the Company. Upon full exercise of the Warrants, the share capital will increase by a maximum of SEK 126,000.00.

**July ends with** Realheart announcing the last day of trading in BTUs and the first day of trading in warrants of series TO3. The number of warrants of series TO3 amounts to 54,910,406. Upon full exercise of all warrants of series TO3, the Company can be provided with a maximum of 27,455,203 new shares, which corresponds to a dilution of 11.7 percent.

**During the first half of August**, the Company announces the appointment of Jimmy Nybom as new interim CFO, during the ongoing recruitment process of a permanent CFO. Jimmy has had extensive contacts with Realheart as the company's auditor during the years 2019-2022 and is therefore well versed in the company's finances and operations.

**In the second half of August**, Realheart announces that it has entered into a collaboration with a leading veterinary large animal unit at the University of Gothenburg in Sweden for the continued preclinical safety evaluation of the Realheart® TAH artificial heart. The purpose is to conduct high-quality animal experimental large animal experiments required to ultimately conduct a clinical study. This will also facilitate the preparation of the clinical trial planned to be conducted in Sweden.

**The final event of the period** is an announcement that the company will present new data from two successful preclinical studies evaluating the treatment safety of the company's total artificial heart Realheart® TAH, at the 30th Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS) 2024, on November 13-15 in Utsunomiya, Japan.



# Significant Events After the End of the Period

**The first event after the end of the period** is an announcement that the Company has published a preclinical study describing a new method to simulate hemolysis in artificial hearts using pumping mechanisms. This unique method will be important in the further development of Realheart® TAH. Based on its innovative approach, the study was awarded the ESAO-SAGE research prize at the 50th Congress of the European Society for Artificial Organs 2024.

**Closer to mid-October**, the company announces a collaboration with Professors Arjang Ruhparwar and Jan Schmitt, at the Department of Cardiothoracic, Transplantation and Vascular Surgery at Hannover Medical School, Hannover, Germany. The collaboration aims to familiarize leading transplant surgeons with Realheart® TAH and gain valuable professional input for the clinical trials. Realheart® TAH is intended for use in patients awaiting heart transplantation or as an alternative to transplantation.

**November begins with** the publication of the communiqué from Realheart's extraordinary general meeting. At the same time, the record date for the reverse share split in the Company is announced as November 22. The reverse share split will take place according to the ratio 1:100, whereby one hundred (100) existing shares will be consolidated into one (1) share.

# Summary of Interim Report

(SEK)

Group Overview	2024-07-01	2023-07-01	2024-01-01	2023-01-01
	2024-09-30	2023-09-30	2024-09-30	2023-09-30
	3 month	3 month	9 month	9 month
Operating income	4 650	878	45 030	104 835
Profit/loss after financial items	-9 914 833	-8 016 849	-24 021 221	-15 081 319
Balance Sheet total assets	92 709 939	150 142 414	92 709 939	150 142 414
Equity / Assets ratio	84%	90%	84%	90%
Earnings per share	-0,05	-0.08	-0,12	-0.16
Number of shares	206 815 258	96 994 446	206 815 258	96 994 446
Earnings per share after dilution*	-0.04	-0.06	-0.10	-0.11

Parent Company Overview	2024-07-01	2023-07-01	2024-01-01	2023-01-01
	2024-09-30	2023-09-30	2024-09-30	2023-09-30
	3 month	3 month	9 month	9 month
Operating income	4 650	878	45 030	104 835
Profit/loss after financial items	-5 903 757	-8 064 889	-19 826 199	-14 813 578
Balance Sheet total assets	96 750 454	148 435 929	96 750 454	148 435 929
Equity / Assets ratio	85%	92%	85%	92%
Earnings per share	-0,03	-0.08	-0,10	-0.15
Number of shares	206 815 258	96 994 446	206 815 258	96 994 446
Earnings per share after dilution*	-0.02	-0.06	-0.08	-0.11

\* Upon full exercise of all options in TO2, TO3 and Option Program 2022/2027.

## Revenue and Result

Scandinavian Real Heart AB is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of received de minimis grants. Research and development costs of Realheart® TAH were capitalized during Q4 with 5.7 MSEK. During the period, capitalized research and development costs were written down by 6.3 MSEK.

### Employees

The number of employees in the Group at the end of the quarter was 11 full-time employees.

### Related Party Transactions

No significant related party transactions have taken place during the period.

### Significant Risks and Uncertainties

Realheart's focus is on getting through the pre-clinical phase (Hemolysis, GLP studies on animals and endurance tests) to be able to start clinical studies. This means that the company must finalize the version of both the controller and the heart pump that will be included in these tests. Realheart must also conduct parallel discussions with the Notified Body in the EU and with the FDA in the US to ensure the fastest and safest route to market for the product.

The company is continuously working on measures to minimize delays. Furthermore, the continued product development requires that the company can solve its financing. The board is continuously working with different scenarios to ensure the company's future operations.

## Financial Position

At the end of the period, the Group's cash and cash equivalents amounted to 31.7 MSEK. At present, the Group does not generate its own positive cash flow and is thus dependent on external financing. In order to solve the longer-term financing needs, the Board of Directors is continuously evaluating options for further capitalization of the company.

# CEO Ina Laura Perkins

During the third quarter, we have taken further steps in the preclinical validation of Realheart® TAH. As a result of the high innovation standard in our device, we have successfully established new important collaborations with the University of Gothenburg and the Hannover Medical School. These collaborations aim to accelerate the preclinical testing of Realheart® TAH, as well as familiarize leading transplantation surgeons with the device ahead of clinical studies. Further, we have proudly announced positive results from three separate studies reaffirming the promising hematological profile as well as the physiological control functions of Realheart® TAH. In parallel, our ongoing activities to optimize the preclinical safety study protocol are moving ahead. Collectively, our step-wise successes reflect the company's work in moving toward the clinical evaluation of our artificial heart.



## Alliances With Leading Clinics Provide Valuable Input Ahead of the Clinical Evaluation

As part of the company's preparations ahead of the clinical evaluation of Realheart® TAH, we strive to establish valuable collaborations with world-leading medical institutions and pioneering transplant surgeons. Therefore, we are very glad that we have been able to announce two new such partnerships, with the University of Gothenburg, and the Hannover Medical School, under the leadership of Professors Göran Dellgren, and Jan Schmitto and Arjang Ruhparwar, respectively.

As part of the agreement with the University of Gothenburg, and Professor Göran Dellgren, Realheart will now expand its preclinical evaluation to the institute's veterinary center. The expansion is an important part of accelerating the company's preclinical safety studies of Realheart® TAH, with the added bonus of allowing the surgical team that will lead future Swedish clinical studies to become familiar with the device. Similarly, the collaboration with Professors Schmitto and Ruhparwar aims to familiarize them, and their team, with Realheart® TAH and provide us with valuable input ahead of our future clinical studies. Partnerships with such esteemed thought leaders are seen as a strong validation of our technology and may very well pave the way for new, similar, collaborations in the future.

## Realheart® TAH is Gaining Attention Among Researchers and Clinical Key Opinion Leaders

In September I had the great privilege to be invited to give a preclinical summary lecture at the EUMS-Mayo Clinic Meeting in Hannover, to visiting surgeons from the Mayo Clinic, U.S. Due to its sizeable clinical organization, high patient throughput and cutting-edge science, Mayo Clinic is deemed the absolute leader in heart transplant research and care in the world. Consequentially, Realheart was invited to give a similar presentation at the Pitié Days, an annual medical event held at the Hôpital Pitié Salpêtrière in Paris. In summary, the meetings provided fruitful discussions and put the spotlight on the high innovation standard of Realheart's technology.

Further, we have been happy to announce important results from three separate nonclinical studies, showcasing the hematological safety and physiological adaptability of Realheart® TAH. At the recent 50th European Society for Artificial Organs Congress 2024, the company's article was awarded the ESAO-SAGE Research Award, again highlighting the potential of our technology. In mid-November, Realheart will attend the 30th Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS) 2024, to present new results showing that Realheart® TAH effectively preserves an important blood coagulant protein. These protective effects may translate into a lower risk of developing internal bleeding in future patients. The results are important to validate the clinical feasibility of Realheart® TAH, as the FDA and other regulatory bodies scrutinize such aspects but will also function as important door-openers to future clinical collaborations.

## Optimization of the Preclinical Safety Protocol is Ongoing

We have previously communicated the need to optimize our surgical protocol to make meaningful advancements in the preclinical safety studies of Realheart® TAH. Thanks to the tireless effort of the experts in our team, as well as external clinical advisors, we have identified the key remaining hurdles in the protocol. We are currently in the process of formulating concrete solutions to these issues together with our development contractors and we look forward, in due time, to presenting new updates from the safety evaluations in our preclinical program.

## Forming Important Alliances to Address a Significant Unmet Global Medical Need

Overall, the third quarter has included several important events that will positively impact the development of Realheart® TAH. There is a clear interest in our company from world-leading surgeons, cardiac clinicians and researchers, as confirmed by new institutional collaborations. Ultimately, we aim to deliver a revolutionary technology for the benefit of vulnerable patients with limited treatment options.

## Ina Laura Perkins

CEO, Scandinavian Real Heart AB



# Scandinavian Real Heart AB

Over the years, Sweden has contributed pioneering medical technology innovations such as the heart and lung machine, the pacemaker and the dialysis machine. The next revolution in the field is the Realheart artificial heart - a Swedish patented innovation that aims to save the lives of patients with heart failure. Every year, around 3 500 people in Sweden die of heart failure. Today, a heart transplant is the only way to save their lives, but the number of donated hearts covers as little as 2% of the need. Realheart's solution could be a crucial step in meeting this challenge.

The foundations of the company were laid in 1999 when doctor Azad Najar began sketching an artificial heart that fully mimics the human heart. In 2007, Azad, together with two partners, founded Scandinavian Real Heart AB. The idea behind Realheart® TAH is based on advanced flow analyses carried out at KTH Royal Institute of Technology between 2002 and 2005.

The goal is to create an artificial heart that mimics the basic principles of the biological heart in terms of structure and function. In this way, pressure and flow can be achieved that both reduce the risk of blood clots and provide energy-efficient blood flow - crucial factors for giving patients a good quality of life.

The development of the product has made great progress over the years. Features such as blood circulation, pump mechanics, pressure and the creation of a natural pulse have been verified through ethically approved animal studies. Today, research and development is conducted in close collaboration with world-leading cardiac surgeons, scientists and engineers, ensuring that the product is continuously optimized and refined.

## Patent Protection

Realheart has granted patents in Sweden, Germany, the United Kingdom, the United States, China and India that protect the original pump principle in TAH. This patent also provides protection for future products: RealVAD® and PulsePump®.

Patent protection is also available on the latest version of Realheart® TAH in Sweden, USA, UK, Australia and Japan. The patent application for it has also been filed for Germany and Canada. The patents provide protection in the markets that are largest and most important for artificial hearts right now, with the exception of China and India which are considered important emerging markets.

In addition to the patent protection described above, Realheart has also approved patents in Sweden, the USA and the United Kingdom for the future Sternal prosthesis product. The application is also submitted in Germany and France. In 2018, a new connection was designed for a simple and secure connection between Realheart® TAH and the body's circulatory system. The patent application for this has also been filed.



*The Realheart® TAH with its external control.*


Finally, the patent application has been filed in two parts for the use of pressure sensors for the automatic control. Given the existing patents together with the new patent applications, the Board believes that the company has a strong patent situation and strong intellectual property protection.

## Mission and Goal

Realheart's mission is, through innovative medical technology solutions, to save the lives of patients with severe heart failure and create the conditions for a life with a continued good quality of life. The company's long-term goal is to commercialize and establish the artificial heart as a treatment option for patients with heart failure. The heart will outperform current solutions by having better and safer functions and it will be used both as a bridge to heart transplants and as a final therapy.

## The Stock

Scandinavian Real Heart AB was listed on the Nasdaq First North Growth Market in December 2021. Nasdaq First North GM is a registered SME marketplace for growth companies that enables Nordic and international entrepreneurs to gain access to growth capital to develop and expand their operations. As of September 30, 2024, the number of shares in Scandinavian Real Heart AB was 206,815,258.



**Giovanni Lauricella**  
*Board Member of Realheart*

## "One of my Missions is to Help Realheart Attract the Investment Needed to Bring Life-Saving Technology to Market."

Giovanni Lauricella has been a member of the Realheart board for about a year. He has Italian blood but was born in New York. Via college in Miami, he recently ended up with family and business in Houston, Texas. Giovanni holds a bachelor's degree in finance and a master's in regulatory affairs and medical law and he understands the regulatory milestones and strategies. His passion for MedTech has guided his career, and over the years, he's worked with medical device venture backable companies, designing and recruiting their teams as a recruiter and also assisting in raising capital.

Can you tell us about your passion for the medical device field?

I had no idea that the work I do today even existed when I first started out, and now it's the only industry I know. Finance was my starting point, but I soon realized that the medical device industry was where I could make a real impact. The turning point for me was realizing how crucial the regulatory process is to making devices safe, effective, and accessible to patients. I've always wanted to contribute to something meaningful that shapes healthcare. Working in regulatory affairs allows me to support innovative technologies in reaching the market while meeting essential safety and legal standards.

**It's incredibly rewarding to know that my work helps doctors and patients access life-saving solutions.**

When Realheart gets as far as it needs to, to commercialize their technology, that can ultimately help the patients. And that's the reason why they started their company. Their business has a fundamental intention to help people, rather than just being some money maker without really having some affect afterward. When you start hearing the patients feedback like 'now I can play with my grandchildren again' or 'I couldn't hear for all my life until now,' how it has either saved patients' life or given them a better quality of life, that is amazing and what's drive you to keep going.

How important is funding to the success of medical device innovations? I would say that funding is essential for success in this field, especially for complex devices like Realheart's Total Artificial Heart, which demand substantial capital to advance through research, clinical trials, and regulatory approval.

**Securing ongoing investment is challenging yet crucial, enabling the company to maintain momentum and meet regulatory and clinical milestones.**

Giovanni has brought consultants as well as introduced investors to Realheart, and he has put Ina Laura on stage in Malta to promote their total artificial heart. He has also helped improve the strategy and raise capital for the company. Giovanni's expertise in strategic fundraising, finance, and medical law allows him to bridge the gap between investors and innovators, helping Realheart attract the investment needed to bring life-saving technology to market.

What do you think is the future of the medical device industry, and what advice would you give to someone looking to enter this field?

I think the future is incredibly bright, we're seeing more advanced devices that can monitor and respond to patient needs in real-time. However, with these advances come new regulatory challenges, and the industry will need to adapt quickly. I'm excited to see how these technologies evolve and how we, as regulators and innovators, can ensure they benefit as many people as possible. My advice would be to remain curious and open-minded. The medical device field is constantly evolving, and there's always something new to learn. Also, don't be afraid to take on challenges that may be outside your comfort zone - whether it's learning about regulatory processes, funding, or technical aspects.



# There's so Much Happening in the Field, and Realheart is at the Forefront of Innovation With their Total Artificial Heart.

Giovanni Lauricella

## How did your journey with Realheart start and how is it like being a board member in Sweden?

I officially joined the board in November 2023, and my first major involvement with Realheart and CEO Ina Laura was when we were hosting a conference in Malta, and we highlighted her on stage. It's been a fantastic year so far. There's so much happening in the field, and Realheart is at the forefront of innovation with their total artificial heart. The company's mission aligns with my personal goals of making a significant impact in healthcare, so it's been a great fit. I'm very grateful to be in a Swedish board, to learn about different cultures and being able to contribute to this company and country. Through board work, you're dealing with different personalities. Everyone has their own perspectives, motivations and thoughts. You must be able to navigate the board, to create relationships, to be polite, but also add value that people can respect. I love people and I love all their differences and uniqueness. It's my job to add value and together we can make a change. It is a great advantage that both me, Magnus and Stuart, who also joined the board at around the same time, come from medical device area.

**We are literally developing the most difficult and life sustaining technology in the medical industry, without exception, and Realheart is one of four companies in the world developing this technology.**

Giovanni brings a strong focus on strategic fundraising and global networking in the MedTech and investment world. He uses his extensive experience in regulatory affairs, market strategy and investor relations to help Realheart secure the financial resources needed for the development and commercialization phases. His ability to bridge the gap between technical teams and investors, ensures that Realheart's value and potential is clearly communicated to stakeholders.

**In summary, the combination of financial insight, strategic guidance and industry knowledge is my main contribution to the Realheart Board.**

**For the past 15 years, Giovanni has been running a recruitment firm for medical device companies, focusing on building teams from R&D all the way through commercialization, recruiting the right talent, both CEOs and entry-level, and building boards. By doing that, he gets a high level of exposure to investors.**

## How does Realheart's TAH differ from other artificial hearts on the market and what do you think will be the next big steps toward commercializing it?

Realheart's focus on replicating both the structure and function of a human heart, sets it apart from other artificial heart technologies. This design aims to improve compatibility within the body and enhance patient outcomes by minimizing the side effects seen in other systems. Realheart's TAH is positioned as an innovative solution that combines safety, effectiveness, and a more life-like experience for patients. The next steps will focus on finalizing the product design and continuing with preclinical and clinical testing. The product has already undergone extensive testing with promising results in animal models. Once we move into human trials, we'll be able to gather even more data to refine the device and ensure it meets all regulatory and clinical requirements. The goal is to create a solution that can truly improve patients' lives while ensuring their safety.

## This technology has the potential to transform cardiology. What makes you most excited about the future of artificial hearts?

The most exciting part is the potential to drastically reduce the number of deaths caused by heart failure. With the advent of devices like Realheart's TAH, we can offer a viable alternative that doesn't rely on donors.

**Imagine a world where patients no longer must wait for a transplant but can receive an artificial heart that provides the same function. That's what we're working towards.**

## What are your top three success factors for your own business?

Number one is that I'm living what I do, that's the most important thing, I think. And I love people. If you don't like people, don't be a leader. Number two is "living without a net", no one in my family has money, so I have nothing keeping me safe in the background. I must ensure that my business goes on, that I can support my family and that my employees have a job to go to. And third, I genuinely love this industry, it's a sexy technology, and I meet brilliant and interesting human beings all over the world.

## And what about Realheart's top three success factors?

The first factor is the smaller sized five-liter heart, I think it's the future for Realheart. The differentiator and the value add to the industry that differentiates them from the competitors. So that's a success factor in terms of technology strategy. The second factor is that the company and the board are open minded to do what it takes. I think that the executive team in the board is open minded for alternatives and additional strategies to grow the company and to save the company. The third one is that it's based in Sweden, a country known for technology. The country is in a financial position to see this as an investment or a philanthropic opportunity to enable Sweden to develop a total artificial heart technology that could literally save or revolutionize the heart failure industry. Sweden is an attractive country to operate in, especially when it comes to research and development.

## How do you view the competition from others, such as Carmat and SynCardia?

I think it's a positive force that validates the need and potential of artificial heart solutions. I know that both Carmat and SynCardia are strong players in the artificial heart space, each with its own approach and technology. Carmat, for example, focuses on a bioprosthetic heart that integrates biological materials, while SynCardia has an FDA-approved artificial heart that has been in use for several years.

**Overall, I see Realheart as complementary within a growing field rather than directly adversarial to other companies. I also believe that the competition from Carmat, SynCardia, and others highlights the critical need for innovation in artificial heart technology and ultimately benefits patients by driving the industry forward.**



# Largest Shareholder in the Company

## per 2024-09-30

	Owner Type	Number of Shares	Votes (%)	Capital %
European Innovation Council Accelerator	State, Municipality & region	18 300 000	8.85%	8.85%
Avanza Pension	Individual	10 116 274	4.89%	4.89%
Nordnet Pensionsförsäkring	Other	8 553 701	4.5%	4.5%
Christer Jönsson	Individual	7 984 354	3.86%	3.86%
Eskilstunahem Fastighets AB	Other	7 900 018	3.82%	3.82%
Fenja Capital Partners A/S	Other	4 509 015	2.18%	2.18%
Abbe Dikmen	Individual	3 983 097	1.93%	1.93%
Jonas Rudberg	Individual	3 665 247	1.77%	1.77%
Najar Medical and Invention AB	Other	3 487 905	1.69%	1.69%
Objective Point Sweden Aktiebolag	Other	2 846 082	1.38%	1.38%
Total 10 Largest Shareholders		72 100 103	34.86%	34.86%
Other		134 715 155	65.14%	65.14%
<b>Total Number of Shares</b>		<b>206 815 258</b>	<b>100.0%</b>	<b>100.0%</b>

**Total Number of Shareholders: 5 010**

### Warrants of Series T02

Two (2) warrants of series T02 entitle the holder to subscribe for one (1) new share in the Company at an exercise price corresponding to seventy (70) percent of the volume-weighted average price (VWAP) of the Company's share ten (10) days prior to the subscription period, but at a maximum of SEK 2. The number of warrants of series T02 will amount to a total of 31,007,599. Upon full exercise of all warrants of series T02, the Company may receive a maximum of 15,503,799 new shares, corresponding to a dilution effect of 7%.

Subscription of shares with the support of warrants of series T02 shall, in accordance with the terms of the warrants, take place during the period from January 2, 2025 up to and including January 31, 2025. Warrants of series T02 will be traded on Nasdaq First North Growth Market during the period from August 11, 2023 to January 29, 2025. The ISIN code for warrants of series T02 is SE0020358166.

### Warrants of Series T03

Two (2) warrants of series T03 entitle the holder to subscribe for one (1) new share in the Company. The subscription price when subscribing for shares with the support of the warrants amounts to seventy (70) percent of the volume-weighted average price of the Company's share ten (10) days before the subscription period. The warrants can be exercised for subscription of new shares during the period from March 3, 2025 to March 31, 2025.

The number of warrants of series T03 amounts to 54,910,406. Upon full exercise of all warrants of series T03, the Company may receive a maximum of 27,455,203 new shares, corresponding to a dilution effect of 13%. Trading in the warrants will take place on Nasdaq First North Growth Market under the ticker "HEART T03" with ISIN code SE0022240214.

### Warrants 2022/2027

In accordance with the decision of the Annual General Meeting in June 2022, 10 employees have subscribed for warrants within the framework of an incentive program, Warrants Program 2022/2027. The transfer was made at the current market value of the options after calculation according to Black & Scholes. Each warrant entitles the holder to subscribe for one new share in Scandinavian Real Heart during the period from August 2, 2027 to August 31, 2027. The subscription price amounts to SEK 9.56

after recalculation after the rights issue 2023. Upon full exercise of the warrants, up to 1,104,449 shares can be issued, which corresponds to a dilution of approximately 0.5 percent calculated on the company's 206,815,258 shares. The average price of ordinary shares during January to March has been below the exercise price of the warrants, so the shares are not included in the calculation of the number of diluted shares in the financial tables.

### Principles for the Preparation of the Interim Report

The condensed financial statements for the third quarter 2024, ending September 30, 2024, have been prepared in accordance with the Swedish Annual Accounts Act (1995:1554) and the Swedish Accounting Board's general advice BFNAR 2012:1 Annual accounts and consolidated accounts ("K3"). The condensed financial statements do not include all the information and disclosures required in the annual financial statements. The same accounting principles, definitions of key figures and calculation methods have been applied as in the annual report for 2023 for both the Group and the parent company.

### Audit Review

The interim report has not been reviewed by the Company's auditor.

### Upcoming Financial Reports

Interim Report Q4 2024 2025-02-26

### Submission of Interim Report

Västerås, September 14, 2024

The Board, Scandinavian Real Heart AB

### For Further Information, Please Contact

#### Ina Laura Perkins

CEO Scandinavian Real Heart AB

Phone: +46 70 406 49 21

E-mail: [inalaura.perkins@realheart.se](mailto:inalaura.perkins@realheart.se)

#### Jimmy Nybom

Interim CFO Scandinavian Real Heart AB

Phone: +46 70 345 72 08

E-mail: [jimmy.nybom@realheart.se](mailto:jimmy.nybom@realheart.se)

# Income Statement in Summary

## GROUP

	(SEK)			
	2024-07-01	2023-07-01	2024-01-01	2023-01-01
	2024-09-30	2023-09-30	2024-09-30	2023-09-30
	3 month	3 month	9 month	9 month
<b>Operating Income</b>				
Net turnover	-	-	-	-
Other operating income	4 650	878	45 030	104 835
	<b>4 650</b>	<b>878</b>	<b>45 030</b>	<b>104 835</b>
<b>Operating Expenses</b>				
Outsourced services	-1 587 654	-499 586	-4 272 421	-2 019 853
Other external expenses	-2 745 081	-8 859 976	-10 910 341	-14 419 114
Personnel cost	-3 116 448	-2 751 593	-10 097 697	-9 827 407
Capitalized expenses on own account	4 550 913	4 189 046	14 128 641	11 769 780
Depreciation and impairment of tangible and intangible fixed assets	-6 774 681	-47 653	-12 036 279	-94 549
Other operating expenses	-88 047	58 481	-372 267	-283 340
	<b>-9 760 998</b>	<b>-7 911 281</b>	<b>-23 560 364</b>	<b>-14 874 483</b>
<b>Operating Profit/Loss</b>	<b>-9 756 348</b>	<b>-7 910 403</b>	<b>-23 515 334</b>	<b>-14 769 648</b>
Other interest income and similar items	1 238	79 605	2 625	80 628
Interest expenses and similar items	-159 723	-186 051	-508 512	-392 299
	<b>-158 485</b>	<b>-106 446</b>	<b>-505 887</b>	<b>-311 671</b>
<b>Profit/Loss After Financial Items</b>	<b>-9 914 833</b>	<b>-8 016 849</b>	<b>-24 021 221</b>	<b>-15 081 319</b>

# Balance Sheet in Summary

## GROUP

	2024-09-30	2023-09-30	(SEK) 2023-12-31
<b>ASSETS</b>			
<b>Fixed Assets</b>			
<i>Intangible fixed assets</i>			
Capitalized expenditure on development, patents, licences and trademarks	56 832 256	102 697 839	56 143 419
<i>Tangible fixed assets</i>			
Equipment, tools, fixtures and fittings	584 317	692 403	707 510
<b>Total Fixed Assets</b>	<b>57 416 573</b>	<b>103 390 242</b>	<b>56 850 929</b>
<b>Current Assets</b>			
<i>Current receivables</i>			
Accounts receivables	-	-	-
Tax receivables	996 853	63 274	-
Other receivables	987 400	1 099 491	801 267
Prepaid expenses and accrued income	1 603 845	1 536 075	1 683 371
	<b>3 588 098</b>	<b>2 698 840</b>	<b>2 484 638</b>
Cash and bank balances	31 705 268	44 053 332	43 302 712
<b>Total Current Assets</b>	<b>35 293 366</b>	<b>46 752 172</b>	<b>45 787 350</b>
<b>TOTAL ASSETS</b>	<b>92 709 939</b>	<b>150 142 414</b>	<b>102 638 279</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
<b>Shareholders' Equity</b>			
Share capital	10 340 763	9 699 445	9 699 445
Ongoing unregistered share issue	-	-	-
Other contributed capital	226 238 083	211 152 817	211 469 023
Other equity incl. profit/loss for the period	-159 074 640	-85 581 936	-139 130 494
<b>Total Equity</b>	<b>77 504 206</b>	<b>135 270 326</b>	<b>82 037 974</b>
<b>Non-Current Liabilities</b>			
Liabilities to credit institutions	4 930 391	7 469 351	6 352 920
<b>Current Liabilities</b>			
Liabilities to credit institutions	1 896 706	1 254 451	1 896 706
Advances from Grants	3 927 231	1 319 595	8 157 140
Accounts payable	2 576 212	3 026 635	1 789 333
Tax liabilities	169 668	205 737	217 885
Other current liabilities	122 732	390 482	473 091
Accrued expenses and deferred income	1 582 793	1 205 837	1 713 230
	<b>10 275 342</b>	<b>7 402 737</b>	<b>14 247 385</b>
<b>TOTAL SHAREHOLDER'S EQUITY AND LIABILITIES</b>	<b>92 709 939</b>	<b>150 142 414</b>	<b>102 638 279</b>

# Cash Flow Statement in Summary

## GROUP

	2024-07-01	2023-07-01	2024-01-01	(SEK) 2023-01-01
	2024-09-30	2023-09-30	2024-09-30	2023-09-30
	3 month	3 month	9 month	9 month
<b>Cash Flow from Operations</b>				
Cash flow from operating activities	-9 914 833	-8016849	-24 021 221	-15 081 319
Adjustment for non-cash items	6 613 013	-241 505	12 359 239	-20 522
	<b>-3 301 820</b>	<b>-8 258 354</b>	<b>-11 661 982</b>	<b>-15 101 841</b>
<b>Cash Flow from Operations Before Changes in Working Capital</b>	<b>-3 301 820</b>	<b>-8 258 354</b>	<b>-11 661 982</b>	<b>-15 101 841</b>
Change in account receivables	-	-	-	-
Change in current receivables	-163 733	-510 513	-1 103 460	761 201
Change in accounts payable	-1 158 640	-4 504 377	786 879	-7 304 750
Change in current liabilities	-533 022	-397 566	-529 113	97 121
<b>Cash Flow From Operating Activities</b>	<b>-5 157 215</b>	<b>-13 670 810</b>	<b>-12 507 676</b>	<b>-21 548 269</b>
<b>Investing Activities</b>				
Assets	-4 676 438	-4 133 309	-16 829 132	-11 467 231
R&D tax refunds	-	7 135 430	-	7 135 430
Investments tangible fixed assets	-	-697 020	-	-697 020
<b>Cash Flow From Investing Activities</b>	<b>-4 676 438</b>	<b>2 305 101</b>	<b>-16 829 132</b>	<b>-5 028 821</b>
<b>Financing Activities</b>				
New share issue	19 190 523	48 583 438	19 190 523	52 821 495
Warrants	-	-	-28 630	-
Change in loans	-474 177	-474 176	-1 422 529	6 549 889
<b>Cash Flow From Financing Activities</b>	<b>18 716 346</b>	<b>48 109 262</b>	<b>17 739 364</b>	<b>59 371 384</b>
<b>Cash Flow for the Period</b>	<b>8 882 693</b>	<b>36 743 553</b>	<b>-11 597 444</b>	<b>32 794 294</b>
<b>Cash and Cash Equivalents at the Beginning of the Period</b>	<b>22 822 575</b>	<b>7 309 779</b>	<b>43 302 712</b>	<b>11 259 038</b>
<b>Cash and Cash Equivalents at the End of the Period</b>	<b>31 705 268</b>	<b>44 053 332</b>	<b>31 705 268</b>	<b>44 053 332</b>



# Income Statement in Summary

## PARENT COMPANY

	(SEK)			
	2024-07-01	2023-07-01	2024-01-01	2023-01-01
	2024-09-30	2023-09-30	2024-09-30	2023-09-30
	3 month	3 month	9 month	9 month
<b>Operating Income</b>				
Net turnover	-	-	-	-
Other operating income	4 650	878	45 030	104 835
	<b>4 650</b>	<b>878</b>	<b>45 030</b>	<b>104 835</b>
<b>Operating Expenses</b>				
Outsourced services	-1 587 654	-499 586	-4 272 421	-2 019 853
Other external expenses	-2 713 649	-8 829 174	-10 694 963	-14 072 531
Personnel cost	-3 116 448	-2 751 593	-10 097 697	-9 827 407
Capitalized expenses on own account	4 550 913	4 189 046	14 128 641	11 769 780
Depreciation and impairment of tangible and intangible fixed assets	-2 796 706	-47 653	-8 058 304	-94 549
Other operating expenses	-88 047	58 481	-372 267	-283 340
	<b>-5 751 591</b>	<b>-7 880 479</b>	<b>-19 367 011</b>	<b>-14 527 900</b>
<b>Operating Profit/Loss</b>	<b>-5 746 941</b>	<b>-7 879 601</b>	<b>-19 321 981</b>	<b>-14 423 065</b>
Interest income and similar items	1 238	763	2 625	1 786
Interest expenses and similar items	-158 054	-186 051	-506 843	-392 299
	<b>-156 816</b>	<b>-185 288</b>	<b>-504 218</b>	<b>-390 513</b>
<b>Profit/Loss After Financial Items</b>	<b>-5 903 757</b>	<b>-8 064 889</b>	<b>-19 826 199</b>	<b>-14 813 578</b>
<b>Profit/Loss Before Taxes</b>	<b>-5 903 757</b>	<b>-8 064 889</b>	<b>-19 826 199</b>	<b>-14 813 578</b>
<b>Net Income for the Period</b>	<b>-5 903 757</b>	<b>-8 064 889</b>	<b>-19 826 199</b>	<b>-14 813 578</b>

# Balance Sheet in Summary

## PARENT COMPANY

	(SEK)		
	2024-06-30	2023-06-30	2023-12-31
	2024-09-30	2023-09-30	2023-12-31
<b>ASSETS</b>			
<b>Fixed Assets</b>			
<i>Intangible fixed assets</i>			
Capitalized expenditure on development, patents, licences and trademarks	45 630 452	92 592 389	45 209 571
<i>Tangible fixed assets</i>			
<b>Equipment, tools, fixtures and fittings</b>	<b>584 317</b>	<b>692 403</b>	<b>707 510</b>
<i>Financial fixed assets</i>			
Shares in group companies	14 195 622	11 320 840	14 195 622
<b>Total Fixed Assets</b>	<b>60 410 391</b>	<b>104 605 632</b>	<b>60 112 703</b>
<b>Current Assets</b>			
Accounts receivable	-	-	-
Receivables from group companies	3 614 598,00	2 961 385	-
Other receivables	987 400	1 099 491	652 100
Prepaid expenses and accrued income	345 646	271 662	455 266
	<b>4 947 644</b>	<b>4 332 538</b>	<b>1 107 366</b>
Cash and cash equivalents	31 392 419	39 497 759	42 001 609
<b>Total Current Assets</b>	<b>36 340 063</b>	<b>43 830 297</b>	<b>43 108 975</b>
<b>TOTAL ASSETS</b>	<b>96 750 454</b>	<b>148 435 929</b>	<b>103 221 678</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
<b>Shareholders' Equity</b>			
Share capital	10 340 763	9 699 445	9 699 445
Fund for development expenditures	38 354 755	85 741 851	38 354 756
<b>Restricted Equity</b>	<b>48 695 518</b>	<b>95 441 296</b>	<b>48 054 201</b>
Share premium reserve	226 238 083	211 152 818	211 469 023
Retained earnings/loss	-172 832 727	-155 947 602	-108 905 341
Profit/loss for the period	-19 826 199	-14 813 578	-67 678 901
<b>Unrestricted Equity</b>	<b>33 579 157</b>	<b>40 391 638</b>	<b>34 884 781</b>
<b>Total Shareholders' Equity</b>	<b>82 274 675</b>	<b>135 832 934</b>	<b>82 938 982</b>
<b>Non-Current Liabilities</b>			
Liabilities to credit institutions	4 930 391	7 469 351	6 352 920
<b>Current Liabilities</b>			
Liabilities to credit institutions	1 896 706	1 254 451	1 896 706
Advances from grants	3 927 231	1 319 595	8 157 140
Accounts payable	1 731 490	757 546	1 471 725
Tax liabilities	169 668	205 737	217 885
Other current liabilities	237 499	390 482	473 091
Accrued expenses and deferred income	1 582 794	1 205 834	1 713 229
	<b>9 545 388</b>	<b>5 133 645</b>	<b>13 929 776</b>
<b>TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES</b>	<b>96 750 454</b>	<b>148 435 930</b>	<b>103 221 678</b>

# Cash Flow Statement in Summary

## PARENT COMPANY

	(SEK)			
	2024-07-01	2023-07-01	2024-01-01	2023-01-01
	2024-09-30	2023-09-30	2024-09-30	2023-09-30
	3 month	3 month	9 month	9 month
<b>Cash Flow From Operations</b>				
Cash flow from operating activities	-5 903 757	-8 064 889	-19 826 199	-14 813 578
Adjustment for non-cash items	2 796 707	47 653	8 058 304	94 549
<b>Cash Flow From Operations Before Changes in Working Capital</b>	<b>-3 107 050</b>	<b>-8 017 236</b>	<b>-11 767 895</b>	<b>-14 719 029</b>
<b>Changes in Working Capital</b>				
Change in accounts receivable	-	-	-	-
Change in current receivables	-732 929	-2 363 322	-3 840 278	-3 465 568
Change in accounts paybles	-1 590 533	-480 520	259 765	-807 014
Changes in current liabilities	-731 267	-397 573	-414 244	210 171
<b>Cash Flow From Operating Activities</b>	<b>-6 161 779</b>	<b>-11 258 651</b>	<b>-15 762 652</b>	<b>-18 781 440</b>
<b>Investing Activities</b>				
Shareholder contribution	-	-	-	-
Investments intangible fixed assets	-3 689 512	-3 855 884	-12 585 901	-10 644 458
Investments tangible fixed assets	-	-697 020	-	-697 020
<b>Cash Flow From Investing Activities</b>	<b>-3 689 512</b>	<b>-4 552 904</b>	<b>-12 585 901</b>	<b>-11 341 478</b>
<b>Financing Activities</b>				
New share issue	19 190 522	48 583 438	19 190 522	52 821 495
Warrants	-	-	-28 630	-
Change in loans	-474 177	-474 176	-1 422 529	6 549 889
<b>Cash Flow From Financing Activities</b>	<b>18 716 345</b>	<b>48 109 262</b>	<b>17 739 363</b>	<b>59 371 384</b>
<b>Cash Flow for the Period</b>	<b>8 865 054</b>	<b>32 297 707</b>	<b>-10 609 190</b>	<b>29 248 466</b>
<b>Cash and Cash Equivalents at the Beginning of the Period</b>	<b>22 527 365</b>	<b>7 200 052</b>	<b>42 001 609</b>	<b>10 249 293</b>
<b>Cash and Cash Equivalents at the End of the Period</b>	<b>31 392 419</b>	<b>39 497 759</b>	<b>31 392 419</b>	<b>39 497 759</b>

# Change in Equity

## GROUP & PARENT COMPANY

GROUP	(MSEK)			
	2024-07-01 2024-09-30	2023-07-01 2023-09-30	2024-01-01 2024-09-30	2023-01-01 2023-09-30
<b>Summary of Changes in Equity</b>				
Equity at the beginning of the period	64 083 715	94 992 896	82 037 974	97 645 222
Other changes in shareholders' equity	-187 700	-189 159	325 561	-115 072
Share issue	23 523 022	48 483 438	19 190 522	52 821 495
Other contributed capital	-	-	-28 631	-
Profit/loss for the period	-9 914 833	-8 016 849	-24 021 221	-15 081 319
<b>Shareholders' Equity at the End of the Period</b>	<b>77 504 206</b>	<b>135 270 326</b>	<b>77 504 206</b>	<b>135 270 326</b>

PARENT COMPANY	(MSEK)			
	2024-07-01 2024-09-30	2023-07-01 2023-09-30	2024-01-01 2024-09-30	2023-01-01 2023-09-30
<b>Summary of Changes in Equity</b>				
Equity at the beginning of the period	64 655 409	95 314 385	82 938 982	97 825 017
Share issue	23 523 022	48 583 438	19 190 522	48 583 438
Other contributed capital	-	-	-28 631	4 238 057
Profit/loss for the period	-5 903 757	-8 064 889	-19 826 199	-14 813 578
<b>Shareholders' Equity at the End of the Period</b>	<b>82 274 675</b>	<b>135 832 934</b>	<b>82 274 675</b>	<b>135 832 934</b>





REALHEART

Kopparbergsvägen 6  
722 13 Västerås  
info@realheart.se

realheart.se